These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33268483)

  • 1. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
    Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
    J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
    Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
    Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
    Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
    J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display.
    Zielonka S; Krah S; Arras P; Lipinski B; Zimmermann J; Boje AS; Klausz K; Peipp M; Pekar L
    Methods Mol Biol; 2023; 2681():231-248. PubMed ID: 37405651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
    Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
    Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
    Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
    Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
    Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
    Front Immunol; 2021; 12():801368. PubMed ID: 35087526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.
    Cao G; Wang J; Zheng X; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Dec; 290(50):29964-73. PubMed ID: 26472927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
    Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
    MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors.
    Kaifu T; Escalière B; Gastinel LN; Vivier E; Baratin M
    Cell Mol Life Sci; 2011 Nov; 68(21):3531-9. PubMed ID: 21877119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
    Zou Y; Bao J; Pan X; Lu Y; Liao S; Wang X; Wang G; Lin D
    PLoS One; 2015; 10(8):e0134568. PubMed ID: 26241657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
    Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
    J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
    Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
    Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies.
    Lee S; Kim JH; Jang IH; Jo S; Lee SY; Oh SC; Kim SM; Kong L; Ko J; Kim TD
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
    Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
    J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
    Semeraro M; Rusakiewicz S; Minard-Colin V; Delahaye NF; Enot D; Vély F; Marabelle A; Papoular B; Piperoglou C; Ponzoni M; Perri P; Tchirkov A; Matta J; Lapierre V; Shekarian T; Valsesia-Wittmann S; Commo F; Prada N; Poirier-Colame V; Bressac B; Cotteret S; Brugieres L; Farace F; Chaput N; Kroemer G; Valteau-Couanet D; Zitvogel L
    Sci Transl Med; 2015 Apr; 7(283):283ra55. PubMed ID: 25877893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.
    Li Y; Wang Q; Mariuzza RA
    J Exp Med; 2011 Apr; 208(4):703-14. PubMed ID: 21422170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.